Imugene Limited (AU:IMU) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited has begun dosing the first patient in its Phase 1 onCARlytics trial, part of the OASIS study, focusing on advanced solid tumors. The trial explores the use of a CD19-expressing oncolytic virus, both as a standalone treatment and in combination with the cancer immunotherapy blinatumomab. This innovative approach aims to make hard-to-treat tumors more recognizable to existing therapies, potentially offering new hope for patients with metastatic cancers.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
